BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

Led by GSK neuro R&D alumni and fueled by $100 million in series A funds, SciNeuro aims to develop  neurodegeneration and neuropsychiatric therapies for the Greater China market through a mix of partnering and in-house R&D....
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the retina intravitreally.  Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

Eli Lilly’s acquisition of Disarm marks the second time an Atlas-incubated newco has turned to the pharma to advance its neurology assets.  Under the deal, Eli Lilly and Co. (NYSE:LLY) will acquire Disarm Therapeutics Inc....
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts. Scribe Therapeutics Inc....
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

The stain of “too high-risk for investment” that plagued neuroscience for years has now worn off, according to a BioCentury analysis of early stage venture investments. Neurology sits second only to cancer...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...
BioCentury | Aug 18, 2020
Deals

Dragonfly’s TrinKET-enhancing cytokine platform sees early win with $475M BMS deal

Dragonfly has struck another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12 program designed to complement its NK cell engager technology and other immunotherapies.  The biotech will receive...
Items per page:
1 - 10 of 427
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

Led by GSK neuro R&D alumni and fueled by $100 million in series A funds, SciNeuro aims to develop  neurodegeneration and neuropsychiatric therapies for the Greater China market through a mix of partnering and in-house R&D....
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

Novartis’ acquisition of Atlas-incubated start-up Vedere Bio will bolster an ophthalmic gene therapy portfolio spearheaded by Luxturna, and will give the Swiss pharma technology to deliver gene therapies to the retina intravitreally.  Novartis AG (NYSE:NVS; SIX:NOVN)...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

Eli Lilly’s acquisition of Disarm marks the second time an Atlas-incubated newco has turned to the pharma to advance its neurology assets.  Under the deal, Eli Lilly and Co. (NYSE:LLY) will acquire Disarm Therapeutics Inc....
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts. Scribe Therapeutics Inc....
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

The stain of “too high-risk for investment” that plagued neuroscience for years has now worn off, according to a BioCentury analysis of early stage venture investments. Neurology sits second only to cancer...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...
BioCentury | Aug 18, 2020
Deals

Dragonfly’s TrinKET-enhancing cytokine platform sees early win with $475M BMS deal

Dragonfly has struck another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12 program designed to complement its NK cell engager technology and other immunotherapies.  The biotech will receive...
Items per page:
1 - 10 of 427